Lyle Small

Founder and interim chief technology officer of Lahjavida, Inc., a cancer research firm focused on developing Dye Drug Conjugates (DDCs) for enhanced chemotherapy delivery.

Best podcasts with Lyle Small

Ranked by the Snipd community

Oct 9, 2024 • 30min

Targeting Tumors: How Dye Drug Conjugates Are Revolutionizing Cancer Treatment

In this discussion, Lyle Small, founder and CTO of Lahjavida, Inc., sheds light on the revolutionary use of Dye Drug Conjugates (DDCs) in cancer treatment. Lyle, an experienced entrepreneur with a background in engineering, explains how DDCs enhance chemotherapy effectiveness by targeting tumor cells more precisely. He details the transition from traditional methods to innovative fluorescent dye applications, revealing exciting advancements that minimize side effects and improve patient outcomes. Tune in to discover the future of cancer therapy!

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app